Chimera Bioengineering, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Mar 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Combination therapy with gold controlled transgenes (US 11,648,277) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 2 fees due Dec 18, 2026
- 1 fee due Feb 8, 2027The maintenance fee for Methods for making novel antigen binding domains (US 11,718,929) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Gold Optimized CAR T-cells (US 10,472,637) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof (US 10,508,152) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,530,272 | Smart CAR Devices, DE CAR Polypeptides, Side CARs and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,508,152 | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,323,248 | Gold Optimized Car T-Cells In force · High confidence | In force | High confidence | |
| US 10,323,249 | Gold Optimized CAR T-cells In force · High confidence | In force | High confidence | |
| US 10,472,637 | Gold Optimized CAR T-cells In force · High confidence | In force | High confidence | |
| US 10,669,549 | Gold Optimized CAR T-cells In force · High confidence | In force | High confidence | |
| US 10,858,660 | Gold Optimized CAR T-cells In force · High confidence | In force | High confidence | |
| US 11,535,853 | Gold Optimized CAR T-cells In force · Medium confidence | In force | Medium confidence | |
| US 11,572,566 | Gold Optimized CAR T-cells In force · Medium confidence | In force | Medium confidence | |
| US 10,222,369 | Methods for Making Novel Antigen Binding Domains In force · High confidence | In force | High confidence |
Also on record, not counted in the 16: 6 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 abandoned · 9 no status recorded